Stenabolic SR-9009

What Is Stenabolic SR-9009?

SR-9009, commonly known as Stenabolic, is a synthetic Rev-Erb alpha (Rev-Erba) agonist developed by Professor Thomas Burris and his team at the Scripps Research Institute. Unlike traditional SARMs that bind to androgen receptors, Stenabolic SR-9009 targets the Rev-Erba nuclear receptor, a protein involved in regulating the body’s circadian rhythm, lipid metabolism, and energy expenditure. This makes SR-9009 a fundamentally different class of research compound to selective androgen receptor modulators like RAD-140 or MK-2866.

The compound was first described in a landmark 2012 study published in Nature (Solt et al.), which demonstrated that synthetic Rev-Erba agonists including SR-9009 could alter circadian behaviour and metabolic parameters in animal models. Since then, Stenabolic has attracted significant research interest for its potential applications in studying metabolic disorders, circadian biology, and exercise physiology.

If you’re looking to buy SR-9009 in the UK, sarms.co.uk supplies research-grade Stenabolic capsules manufactured in a GMP-certified UK facility with 99%+ HPLC-verified purity and a Certificate of Analysis included with every order. We offer free next-day UK delivery on all Stenabolic orders. Whether you’re searching for SR-9009 for sale UK, Stenabolic capsules, or the best SR-9009 UK supplier, our independently tested Stenabolic meets the highest research-grade quality standard available.

How Does Stenabolic SR-9009 Work? Mechanism of Action

Stenabolic SR-9009 functions as a Rev-Erba agonist, meaning it activates the Rev-Erba nuclear receptor. Rev-Erba is a core component of the molecular clock that governs circadian rhythms in virtually every tissue in the body. When SR-9009 binds to and activates Rev-Erba, it modulates the expression of genes involved in several key metabolic processes:

• Lipid metabolism – Rev-Erba activation by SR-9009 has been shown to suppress genes involved in lipogenesis (fat production) while increasing genes involved in fatty acid oxidation
• Glucose homeostasis – studies in animal models show SR-9009 can influence hepatic glucose production and insulin sensitivity
• Mitochondrial biogenesis – activation of Rev-Erba increases the number and activity of mitochondria in skeletal muscle, which is linked to energy expenditure and endurance capacity
• Circadian clock regulation – by modulating core clock gene expression, SR-9009 can shift circadian phase and alter the timing of metabolic processes
• Inflammatory pathways – Rev-Erba plays a role in suppressing inflammatory gene expression, and SR-9009 has shown anti-inflammatory properties in preclinical models

Crucially, because SR-9009 does not interact with the androgen receptor, it does not cause testosterone suppression and does not require post-cycle therapy (PCT). This is one of the key differences between Stenabolic and true SARMs like RAD-140 Testolone or LGD-4033 Ligandrol.

Published Research on Stenabolic SR-9009

The research base for SR-9009 is anchored by several significant studies. All findings below are from preclinical (animal or in vitro) research conducted under controlled laboratory conditions.

• Solt et al. (2012), Nature – the foundational study that characterised SR-9009 as a Rev-Erba agonist. Mice treated with SR-9009 showed reduced fat mass, improved lipid profiles, and increased endurance capacity on treadmill tests. This study established the core pharmacological profile of Stenabolic. (PMID: 22660318)
• Woldt et al. (2013), Nature Medicine – demonstrated that Rev-Erba activation by SR-9009 increased mitochondrial content and oxidative function in skeletal muscle, resulting in enhanced running endurance in mice. (PMID: 24013700)
• Sulli et al. (2018), Nature – investigated SR-9009 and SR-9011 in cancer cell models, finding that Rev-Erba agonists displayed selective cytotoxicity against cancer cells while sparing normal cells. (PMID: 29364872)
• Dierickx et al. (2019), PNAS – an important study noting that some effects attributed to SR-9009 may be Rev-Erb-independent, occurring even in Rev-Erba/b double-knockout cells. This suggests the compound may have additional pharmacological targets beyond Rev-Erba. (PMID: 31142646)
• Cutler et al. (2022), Drug Testing and Analysis – characterised the in vitro metabolism of SR-9009 and identified N-dealkylated metabolites as detection targets in doping control, confirming the compound’s status as a monitored substance in competitive sport. (PMID: 34224639)

Important: No human clinical trials of SR-9009 have been published to date. All efficacy data comes from animal and in vitro studies. sarms.co.uk supplies Stenabolic exclusively for legitimate research purposes.

Stenabolic SR-9009 vs. SARMs: Key Differences

Although Stenabolic SR-9009 is often grouped with SARMs for convenience, it is not a selective androgen receptor modulator. The distinction matters for researchers:

• Target receptor: SARMs bind to the androgen receptor (AR). SR-9009 binds to Rev-Erba, a nuclear receptor involved in circadian and metabolic regulation
• Testosterone suppression: SARMs like RAD-140 and LGD-4033 can suppress the HPTA axis. SR-9009 does not affect testosterone production
• PCT requirement: SARMs may require post-cycle therapy. SR-9009 does not
• Primary research focus: SARMs are studied for muscle and bone. SR-9009 is studied for metabolism, circadian biology, endurance, and inflammation
• Half-life: SR-9009 has a notably short plasma half-life in rodent models, which presents challenges for research protocol design
• Bioavailability: Early research suggested limited oral bioavailability in rodents, though subsequent studies using alternative delivery methods have achieved better results

For researchers specifically interested in androgen-receptor-mediated effects, SARMs like MK-2866 Ostarine or YK-11 may be more relevant. For circadian rhythm, metabolic, and endurance research, SR-9009 occupies a unique niche.

SR-9009 Dosage and Administration in Research Settings

The following dosage information is derived from published animal studies and is provided for research reference only. SR-9009 Stenabolic is sold by sarms.co.uk exclusively for research use and is not intended for human consumption.

• Rodent research doses: The Solt et al. (2012) Nature study used 100 mg/kg administered intraperitoneally (IP) in mice. The Woldt et al. (2013) study used similar protocols
• Administration routes studied: Intraperitoneal injection (most common in published research), subcutaneous injection, and oral administration
• Dosing frequency: Due to SR-9009’s short half-life, most rodent protocols use twice-daily or more frequent dosing
• Duration: Published studies have used treatment periods ranging from 7 to 30 days in rodent models

Note: Rodent doses do not translate directly to other species. Researchers should consult the primary literature and relevant ethical guidelines when designing protocols.

Research Applications for Stenabolic SR-9009

SR-9009 is actively studied across several research domains. Current areas of investigation include:

• Circadian rhythm disorders – SR-9009 can phase-shift the molecular clock, making it a tool for studying jet lag, shift-work-related metabolic disruption, and circadian misalignment
• Obesity and metabolic syndrome – preclinical data shows SR-9009 reduces fat mass and improves lipid profiles in diet-induced obesity models
• Exercise physiology – the compound’s effects on mitochondrial biogenesis and running endurance make it relevant to studying the molecular basis of exercise capacity
• Type 2 diabetes research – SR-9009’s effects on hepatic glucose output and insulin sensitivity are being investigated in metabolic disease models
• Oncology – following the Sulli et al. (2018) findings on selective cancer cell cytotoxicity, SR-9009 is being explored in cancer biology research
• Neuroinflammation – Rev-Erba’s role in inflammatory pathways has led to investigation of SR-9009 in models of neuroinflammatory disease
• Cardiovascular research – Rev-Erba influences cardiac gene expression, and SR-9009 has been studied in models of cardiac hypertrophy and atherosclerosis

Why Buy Stenabolic SR-9009 from sarms.co.uk?

When you buy SR-9009 UK from sarms.co.uk, you receive a research compound manufactured to the highest standards:

• 99%+ purity verified by independent HPLC analysis
• Certificate of Analysis (COA) included with every order, documenting batch purity and identity
• UK manufactured in a GMP-certified facility
• Free next-day UK delivery on all orders
• International shipping available worldwide
• Batch-to-batch consistency with strict quality control protocols

We supply SR-9009 Stenabolic exclusively for legitimate research use. Every batch undergoes independent third-party testing before release, and full analytical certificates are available for download from your order confirmation page.

Storage and Handling

• Store in a cool, dry place away from direct sunlight
• Keep sealed when not in use to prevent moisture absorption
• Recommended storage temperature: 15-25 degrees C (room temperature)
• Keep out of reach of children and pets
• For research use only – not for human consumption

Frequently Asked Questions About Stenabolic SR-9009

Is SR-9009 a SARM?

No. SR-9009 (Stenabolic) is a Rev-Erba agonist, not a selective androgen receptor modulator. It does not bind to the androgen receptor. It is often categorised alongside SARMs for convenience because it is sold by the same suppliers and used in related research contexts, but its mechanism of action is entirely different.

Does Stenabolic SR-9009 suppress testosterone?

No. Because SR-9009 does not interact with the androgen receptor or the HPTA axis, it does not suppress endogenous testosterone production. This means no post-cycle therapy (PCT) is required, unlike with SARMs such as RAD-140 or LGD-4033.

Is SR-9009 legal in the UK?

SR-9009 is legal to purchase in the UK for research purposes. It is not classified as a controlled substance under the Misuse of Drugs Act or the Psychoactive Substances Act. However, it is not approved for human consumption by the MHRA and is listed by WADA as a prohibited substance in competitive sport.

Where can I buy SR-9009 Stenabolic in the UK?

You can buy research-grade SR-9009 directly from sarms.co.uk. We supply HPLC-tested Stenabolic manufactured in a UK GMP facility with 99%+ verified purity, COA included, and free next-day delivery across the UK.

What is the price of SR-9009 in the UK?

SR-9009 Stenabolic is competitively priced at sarms.co.uk. Check the product listing above for current pricing, quantity options, and any active promotions. Bulk research orders may qualify for additional discounts.

Can SR-9009 be stacked with SARMs?

In research settings, SR-9009 is sometimes studied alongside SARMs because their mechanisms of action do not overlap. Since Stenabolic targets Rev-Erba while SARMs target the androgen receptor, there is no direct pharmacological competition. Researchers studying metabolic and anabolic pathways simultaneously may find combinations relevant. See our SARM stacks category for pre-configured research combinations.

What is the half-life of SR-9009?

Published rodent pharmacokinetic data indicates SR-9009 has a short plasma half-life, generally reported as approximately 4 hours in mice. This short half-life is a significant consideration in research protocol design and has prompted investigation into alternative delivery methods and dosing schedules.

Does SR-9009 have side effects?

No human clinical trials have been conducted, so a definitive human side-effect profile does not exist. In published animal studies, SR-9009 was generally well tolerated at the doses tested. The Dierickx et al. (2019) study noted that some cellular effects may be Rev-Erb-independent, which warrants consideration in research design.

How does SR-9009 compare to Cardarine GW-501516?

Both compounds are non-SARMs studied for endurance and metabolic effects, but they work through different mechanisms. Cardarine GW-501516 is a PPARdelta agonist that increases fatty acid oxidation. SR-9009 is a Rev-Erba agonist that modulates the circadian clock and mitochondrial biogenesis. Both are non-suppressive and do not require PCT. They are sometimes combined in research protocols.

What is the difference between SR-9009 and SR-9011?

SR-9009 and SR-9011 are both synthetic Rev-Erba agonists developed by the same research group. They share the same target receptor but have different chemical structures. The Sulli et al. (2018) study investigated both compounds in cancer models. SR-9009 is more widely available and more commonly referenced in the literature.

Is Stenabolic banned in sport?

Yes. SR-9009 is included on the World Anti-Doping Agency (WADA) Prohibited List under the category of hormone and metabolic modulators. It is banned both in-competition and out-of-competition. The Cutler et al. (2022) study specifically developed detection methods for SR-9009 metabolites in doping control samples.

How should I store SR-9009?

Store SR-9009 at room temperature (15-25 degrees C) in a cool, dry place away from direct sunlight. Keep the container sealed when not in use to prevent moisture absorption. Properly stored, the compound remains stable for the duration indicated on the product label.

Related Research Compounds

Researchers working with SR-9009 Stenabolic may also be interested in the following compounds available from sarms.co.uk:

• Cardarine GW-501516 – PPARdelta agonist researched for endurance and fat metabolism
• RAD-140 Testolone – potent SARM studied for lean mass and neuroprotection
• MK-677 Ibutamoren – growth hormone secretagogue (non-SARM)
• MK-2866 Ostarine – mild SARM studied for muscle and bone preservation
• LGD-4033 Ligandrol – SARM researched for muscle mass and strength
• Andarine S4 – SARM studied for bone mineral density and lean tissue
• YK-11 – steroidal SARM with myostatin-inhibiting properties
• ACP-105 – partial androgen receptor agonist with a favourable potency-to-side-effect ratio

Browse our full research compound catalogue or explore compounds by goal: SARMs for bulking | SARMs for cutting | SARM stacks.

References and Further Reading

• Solt, L.A. et al. (2012). Regulation of circadian behaviour and metabolism by synthetic REV-ERB agonists. Nature, 485, 62-68. PMID: 22660318
• Woldt, E. et al. (2013). Rev-Erba modulates skeletal muscle oxidative capacity by regulating mitochondrial biogenesis and autophagy. Nature Medicine, 19, 1039-1046. PMID: 24013700
• Sulli, G. et al. (2018). Pharmacological activation of REV-ERBs is lethal in cancer and oncogene-induced senescence. Nature, 553, 351-355. PMID: 29364872
• Dierickx, P. et al. (2019). SR9009 has REV-ERB-independent effects on cell proliferation and metabolism. PNAS, 116(25), 12147-12152. PMID: 31142646
• Cutler, C. et al. (2022). In vitro metabolism of the REV-ERB agonist SR-9009. Drug Testing and Analysis, 14(1), 169-174. PMID: 34224639

Disclaimers

• SR-9009 Stenabolic is sold exclusively for research purposes and is not intended for human consumption
• This product is not a medicine and has not been approved by the MHRA or any regulatory body for therapeutic use
• All research data cited above comes from preclinical studies – no human clinical trials have been published
• sarms.co.uk does not encourage or condone the use of this compound outside legitimate research settings
• Researchers are responsible for ensuring their use complies with all applicable laws and institutional guidelines
• Nothing on this page should be interpreted as medical, nutritional, or therapeutic advice

Content last reviewed: 24 February 2026